Paul Yehuda Klein, PSYD | |
415 Cambridge Avenue Suite 4, Palo Alto, CA 94306-1600 | |
(650) 921-1188 | |
(831) 338-4440 |
Full Name | Paul Yehuda Klein |
---|---|
Gender | Male |
Speciality | Psychologist |
Location | 415 Cambridge Avenue Suite 4, Palo Alto, California |
Accepts Medicare Assignments | Medicare enrolled and may accept medicare through third-party reassignment. May prescribe medicare part D drugs. |
Identifier | Type | State | Issuer |
---|---|---|---|
1558304089 | NPI | - | NPPES |
PSY 19125 | Other | CA | CLINICAL PSYCHOLOGIST # |
Taxonomy | Type | License (State) | Status |
---|---|---|---|
103T00000X | Psychologist | PSY19125 (California) | Primary |
Entity Name | One Medical Group Inc |
---|---|
Entity Type | Part B Supplier - Clinic/group Practice |
Entity Identifiers | NPI Number: 1467781641 PECOS PAC ID: 2567623739 Enrollment ID: O20120416000113 |
News Archive
"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.
Data gathered from real-world vaccination programs following a single dose of Pfizer vaccine administration shows a reduction of 51.4% in infection risk and effectiveness of 54.4% against symptomatic coronavirus disease 2019 (COVID-19), matching clinical trial results.
Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB: INKN), an innovative nanotechnology company that develops products, licenses its patent-pending technologies and acquires related assets in three core vertical markets: (i) solar energy production, (ii) medical diagnostics and sensors and (iii) biotechnology research and development tools, today announced that Dr. Michelle Khine, Ph.D., the scientific founder of Shrink's nanofabrication platform, was named by MIT Technology Review as one of the top 35 global innovators under the age of 35.
Teva Pharmaceutical Industries Ltd. commented today on the U.S. Food and Drug Administration's response to a citizen petition questioning the approval criteria for a generic Lovenox (enoxaparin sodium) injection and its subsequent approval of another generic filer's Abbreviated New Drug Application.
Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.
› Verified 4 days ago
Mailing Address | Practice Location Address |
---|---|
Paul Yehuda Klein, PSYD 415 Cambridge Ave Ste 4, Palo Alto, CA 94306-1608 Ph: (650) 921-1188 | Paul Yehuda Klein, PSYD 415 Cambridge Avenue Suite 4, Palo Alto, CA 94306-1600 Ph: (650) 921-1188 |
News Archive
"VONVENDI [von Willebrand factor (Recombinant)]", the new drug from Baxalta Incorporated, a global biopharmaceutical company recently spun off from Baxter International, has just been approved by the United States Food and Drug Administration.
Data gathered from real-world vaccination programs following a single dose of Pfizer vaccine administration shows a reduction of 51.4% in infection risk and effectiveness of 54.4% against symptomatic coronavirus disease 2019 (COVID-19), matching clinical trial results.
Shrink Nanotechnologies, Inc. ("Shrink") (OTCBB: INKN), an innovative nanotechnology company that develops products, licenses its patent-pending technologies and acquires related assets in three core vertical markets: (i) solar energy production, (ii) medical diagnostics and sensors and (iii) biotechnology research and development tools, today announced that Dr. Michelle Khine, Ph.D., the scientific founder of Shrink's nanofabrication platform, was named by MIT Technology Review as one of the top 35 global innovators under the age of 35.
Teva Pharmaceutical Industries Ltd. commented today on the U.S. Food and Drug Administration's response to a citizen petition questioning the approval criteria for a generic Lovenox (enoxaparin sodium) injection and its subsequent approval of another generic filer's Abbreviated New Drug Application.
Ambit Biosciences Corporation and Astellas Pharma Inc. today announced that they have entered into a worldwide agreement to jointly develop and commercialize FLT3 kinase inhibitors in oncology and non-oncology indications.
› Verified 4 days ago
Dr. Zoi Dorit Eliou, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 665 Lytton Ave # 4, Palo Alto, CA 94301 Phone: 650-704-9424 | |
Dr. Zahra Murtaza, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 650 Clark Way, Palo Alto, CA 94304 Phone: 650-617-3829 | |
Diana Naranjo, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 401 Quarry Rd, Child And Adolescent Psychiatry, Palo Alto, CA 94304 Phone: 650-723-5511 Fax: 650-724-7389 | |
Susan Spinrad, PH.D. Psychologist Medicare: Not Enrolled in Medicare Practice Location: 560 Oxford Ave, Suite 3b, Palo Alto, CA 94306 Phone: 650-599-5825 | |
Dr. Lital Koropitzer, PSYD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 825 El Camino Real, Palo Alto, CA 94301 Phone: 650-223-6400 | |
Barbara M Sourkes, PHD Psychologist Medicare: Medicare Enrolled Practice Location: 725 Welch Rd, Palo Alto, CA 94304 Phone: 650-497-8000 | |
Dr. Ferol F. Larsen, PHD Psychologist Medicare: Not Enrolled in Medicare Practice Location: 555 Middlefield Rd, Palo Alto, CA 94301 Phone: 650-326-6896 Fax: 650-326-6896 |